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SUMMARY
We have measured the effects of ephedrine, adren-
aline, noradrenaline and isoprenaline on halothane-
induced contractures in muscle biopsies from
patients potentially susceptible to malignant
hyperthermia (MH). At concentrations of
4-24 mmollitre'7, ephedrine induced in vitro con-
tractures in halothane 0.44 mmol litre'1 -prechal-
lenged muscle, whilst adrenaline, noradrenaline
and isoprenaline had no effect. There was a shift of
the ephedrine concentration-response curve to the
left and an increased maximum muscle contracture
in the MH susceptible group compared with the
MH negative group (P < 0.001). We conclude that
ephedrine increased halothane-induced muscle
contractures in vitro either by an unknown phar-
macological mechanism or by an adrenergic stimu-
lation which was different from those of the other
investigatedadrenoceptoragonists. (Br. J. Anaesth.
1993; 70:76-79)
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Malignant hyperthermia (MH) is characterized clin-
ically by a life-threatening hypermetabolic reaction
that is attributed to an underlying muscle disease.
Skeletal muscle from MH susceptible (MHS) indiv-
iduals demonstrates abnormal in vitro contractures
to halothane, in contrast with muscle bundles from
MH negative (MHN) subjects [1,2]. In vitro muscle
contractures are characterized by an increase in
baseline tension and are related to an increased
myoplasmic calcium concentration [CaJ+], [3]. There
is controversy as to whether or not the sympathetic
system is involved primarily or as a secondary
response to MH [4], and less is known about the
effects of adrenergic agents on muscle metabolism in
humans with an acute MH episode. Therefore, we
have investigated the effects of different adreno-
ceptor agonists on halothane-induced muscle con-
tractures in vitro in patients potentially susceptible
to MH. Some of these results have been published
previously in abstract form [5].
PATIENTS AND METHODS
We studied 42 potentially MHS individuals after
approval by the University of Basel's Hospital Ethics
Committee. All patients gave informed written
consent. Biopsies were taken from the vastus medi-
alis muscle under regional anaesthesia with a femoral
nerve block using 1.5 % mepivacaine 5-7.5 mg kg"1.
The muscle tissue was maintained in Krebs-Ringer
solution oxygenated with 5% carbon dioxide in
oxygen (carbogen) until the experiments were per-
formed. Muscle bundles, approximately 2.5 cm long
and 2-3 mm in diameter, were mounted in a test bath
containing Krebs-Ringer solution. Temperature was
maintained at 37 °C and the bath was bubbled
continuously with carbogen. Supramaximal elec-
trical stimulation at 0.2 Hz was used to demonstrate
the viability of the muscle bundle. MH susceptibility
was evaluated with two halothane and two caffeine
tests on four different muscle bundles, and MH
diagnosis was made according to a standardized
procedure [2, 6].
Surplus muscle bundles were challenged for 10
min with halothane 0.44 mmol litre"1 in the test
bath, corresponding to 2 % in the gas phase, followed
by incremental doses of adrenaline (n = 3), noradren-
aline (n = 6), isoprenaline (n = 3) or ephedrine (n =
42). Twelve bundles were pretreated with incremen-
tal doses of ephedrine 4-24 mmol litre"1 before the
halothane 0.44 mmol litre"1 challenge. All drugs
were dissolved in Krebs-Ringer solution (pH 7.4)
before addition to the test bath. In preliminary
experiments, concentrations between 1 nmol litre"1
and 1 mmol litre"1 of all adrenergic agents studied
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did not initiate any muscle contractures [unpub-
lished results], and thus each adrenoceptor agonist
was evaluated at greater concentrations: 4, 8, 12, 16
and 24 mmol litre"1. Drug concentrations were main-
tained for at least 3 min or until a steady state in
baseline tension was achieved. Muscle contractures
were recorded for each concentration of the various
agents. The baseline value just before addition of the
first dose of an adrenergic agonist was used as the
zero level.
Drugs were obtained from the following com-
mercial sources: halothane from Halocarbon Labora-
tories, Hackensack, NJ, U.S.A.; pure caffeine
from Merck, Darmstadt, Germany; (— )-adrenaline
hydrochloride (HC1), (— )-noradrenaline HC1,
(— )-isoprenaline HC1, (— )-ephedrine HC1 from
Sigma Chemical Co., St Louis, MO, U.S.A.
Data analysis
Ephedrine concentration-response curves were
calculated by non-linear regression analysis accord-
ing to the sigmoidal maximum effect model (Hill
equation) (SAS, Release 6.03, U.S.A.). Data are
presented as mean (SEM) and 95 % confidence
intervals (95 % CI). Statistical analyses were per-
formed using multiple one-sided or two-sided
Student's t tests with Bonferroni correction as
appropriate. P < 0.05 was considered to represent a
significant difference between the groups.
RESULTS
Sixteen individuals were classified as MHN, while
26 patients were considered to be clinically MHS
(fig. 1). The clinically MHS group consisted of 17
individuals who had abnormal contracture tests to
halothane and caffeine challenges and a second group
of nine MH equivocal patients (MHEh) with
abnormal halothane but normal caffeine contracture
tests.
In muscle bundles from 12 patients (MHN: n =
5; MHS: n = 7), administration of ephedrine before
halothane did not produce any contractures. How-
ever, when halothane was added to the test bath after
pretreatment with ephedrine, all muscle bundles
demonstrated contractures (12.6 (3.6) mN (95% CI
2.6-22.6 mN) in the MHN gTOup compared with
43.9 (10.3) mN (95 % CI 18.6-69.1 mN) in the MHS
group).
After the halothane 0.44 mmol litre'1 challenge,
there were no muscle contractures in bundles of
MHS individuals after addition of adrenaline, nor-
adrenaline or isoprenaline to the test bath, whilst
ephedrine induced dose-dependent muscle contrac-
tures in all these muscle bundles (table I, fig. 2).
There was a significant shift of the ephedrine
concentration-response curve to the left for the
MHS group compared with the MHEh and MHN
groups (table II, fig. 3). Eight patients had to be
excluded for the calculations of EC60 and the
maximum effect (£max), because there were no
muscle contractures in response to ephedrine (n = 4
in the MHN group) or because £max was not
achieved in the range of the investigated concentra-
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FIG. 1. Classification of 42 patients investigated with in vitro
muscle contracture tests according to the procedure of the
European Malignant Hyperpyrexia Group [2]. For the diagnosis
of MH susceptibihty the threshold concentrations of halothane
and caffeine were used which initiated an in vitro muscle
contracture > 2 mN. MHN (CO (" = 16) = MH negative; MHS
(#) (n = 17) = MH susceptible (abnormal halothane and ab-
normal caffeine contracture tests); MHEh (A) (n = 9) = MH
equivocal (abnormal halothane but normal caffeine contracture
tests).
TABLE I. In vitro contractures (^ 2 mN) initiated by various
adrenoceptor agonists in 29 muscle bundles from MHS subjects. Each
adrenoceptor agonist was evaluated at increasing concentrations (4,
8, 12, 16 and 24 mmol litre' *) in the presence of halothane
0.44 mmol litre-'
Number of Number
contractures tested
(— )-Ephedrine
( — )-Adrenaline
(— )-Noradrenaline
(— )-Isoprenaline
(— )-Ephedrine after (— )-adrenaline
(— )-Ephedrine after (— )-noradrenaline
(— )-Ephedrine after (— )-isoprenaline
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FIG. 2. Representative curve of halothane and ephedrine effects on
the in vitro muscle contracture of an MHS individual. Contrac-
tions were elicited using supramaximal electrical stimulation
(0.2 Hz) to prove the viability of the muscle bundle. Halothane
and ephedrine were added to the test bath in increasing
concentrations as indicated (labels 8 and 16 (mmol litre"1) omitted
for ephedrine, for clarity.)
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TABLE II. In vitro effect of ephedrine on halothane-induced muscle
contractures {mean {SEM) [95% confidence intervals}). Significant
changes {multiple one-sided t test with Bonferroni correction):
*P < 0.05 {compared with MHN group); + P < 0.05 {compared
with MHEh group); ***P < 0.001 {compared with MHN group)
n £rnax (mN) ECW (tnmol litre"1)
MHN
MHEh
MHS
12
15
17(3.2)
[10-24]
20 (3.9)
[11-30]
29 (4)*
[20-38]
11.8(1.1)
[9.3-14]
9.4(1.9)
[4.8-14]
4.6(1)+***
[2.5-6.8]
2 4 6 8 10 12 14 16 18 20 22 24
Ephedrine (mmol litre"1)
FIG. 3. Mean (SEM) in vitro effect of ephedrine on halothane-
induced contractures in muscle bundles from patients potentially
susceptible to malignant hyperthermia. MHS(#) (n = 17) => MH
susceptible (abnormal halothane and caffeine contracture); MHEh
(A) (n = 9) = MH equivocal (abnormal halothane but normal
caffeine contracture); MHN (O) (" = 16) = MH negative.
tions (n = 1 in the MHN group, n = 2 in the MHEh
group and n = 1 in the MHS group).
DISCUSSION
In this study, ephedrine 4-24 mmol litre"1 increased
halothane-induced in vitro muscle contractures,
whilst adrenaline, noradrenaline and isoprenaline
had no effect. There was a statistically significant
shift of the ephedrine concentration-response curve
to the left in the MHS group compared with the
MHN group. These data suggest the possibility that
ephedrine increased muscle metabolism in vitro.
However, the exact mechanism of the in vitro effect
of ephedrine on skeletal muscle is speculative.
In general, ephedrine is considered to have direct
and indirect sympathomimetic effects, but the exact
pharmacological mechanism(s) is not known [7].
Because inositol 1,4,5-triphosphate (IP3) has been
found to be increased in muscle tissue from MHS
pigs and MHS humans [8, 9], one could speculate
that ephedrine might increase intracellular IP3
concentrations and thereby increase halothane-
induced muscle contractures. Alternatively, or in
addition to IP3, it may be that ephedrine effects are
mediated indirectly by cyclic AMP, comparable to
the effects of theophylline or caffeine on skeletal
muscle in vitro [10]. Recent work has shown the
possible involvement of a mutation of the ryanodine
receptor gene as the primary defect in MHS
individuals [11, 12]. Therefore, it may be interesting
to determine if ephedrine interacts directly or
indirectly with the ryanodine receptor.
If ephedrine initiates muscle contractures by an
adrenergic effect, this mechanism must differ from
classical adrenergic stimulation because adrenaline,
noradrenaline and isoprenaline did not have similar
effects. Little is known about the adrenergic effects
on halothane-induced in vitro muscle contractures.
To our knowledge, only noradrenaline in porcine
skeletal muscle [13] and salbutamol, a beta2-adreno-
ceptor agonist, in human skeletal muscle have been
investigated [14]. Both adrenoceptor agonists did not
potentiate halothane-induced muscle contractures.
Our study provides additional evidence that the
sympathomimetic system does not initiate MH
primarily [15, 16], as we did not find any con-
tracrures in muscle bundles from MHS individuals
after challenges with adrenaline or noradrenaline.
The clinical relevance of in vitro muscle investiga-
tions, as performed in the present study, is unclear,
as we used ephedrine in concentrations of
4-24 mmol litre"1, 1000-2000-fold greater than clin-
ically relevant plasma concentrations. However,
these large concentrations of ephedrine in vitro could
reflect the requirement that effective tissue con-
centrations can be achieved by diffusion, in contrast
to the situation in vivo when ephedrine is brought
into muscle tissue by capillary circulation. Clinically,
ephedrine increases energy expenditure [17, 18] and
has been proposed as a thermogenic drug for the
treatment of obesity [19] and cyclical hypothermia
[20] or for the improvement of cold tolerance [21].
Leg oxygen consumption increased 60% after
ephedrine administration and it was speculated that
50 % of the increase in oxygen consumption induced
by ephedrine may take place in skeletal muscle [17].
In anaesthetics, ephedrine is used for vasopressor
therapy in hypotension as a result of regional or
general anaesthesia [21]. To our knowledge, there
are no clinical data suggesting ephedrine as a MH
trigger. However, these data suggest the use of
alternative adrenergic drugs if cardiovascular in-
stability is associated with a hypermetabolic state in
MHS individuals.
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